Parkinson’s disease and loneliness: “people are hungry for some connection”
Author: Johanna Stiefler JohnsonPublished: 25 February 2021
Prep: Cook: Serves:
Dr Indu Subramanian, a movement disorder neurologist based in Los Angeles, US, shares why social engagement is crucial for the wellbeing of people with Parkinson’s disease – and how Covid-19 has “magnified” the challenges caused by loneliness
“Humans are social creatures – and we need connection just like we need water and shelter.”
Before Covid-19 began to spread in the US, movement disorder neurologist Dr Indu Subramanian and her team were conducting research into the effect of isolation on Parkinson’s disease symptoms. The pandemic, and the worldwide social distancing mandates that followed, increased the urgency of their research paper – and the relevance of their findings.
Subramanian, who is the director of a Veterans Affairs Parkinson’s Disease Research, Education and Clinical Centre in Los Angeles, US, became interested in the effect of isolation after learning about the work of psychologist Julianne Holt-Lunstad. Holt-Lunstad found that loneliness can have as detrimental an impact on mortality as smoking up to 15 cigarettes a day – and is also comparable with the negative effects of obesity, physical inactivity and air pollution.
“To define it, loneliness is a subjective feeling about the relationships you want and the perception of what you have – it’s this gap between them,” says Subramanian. “I started thinking about this in relation to the Parkinson’s patient population.”
As part of the research study, Subramanian and her team analysed survey results from just over 1,500 people with Parkinson’s disease. The data was gathered in collaboration with Dr Laurie Mischley, associate clinical investigator at Bastyr University Research Institute in Kenmore, US. Participants responded to a series of questions related to social satisfaction and activities, to assess how loneliness impacted symptom severity and quality of life.
The study revealed that individuals who reported being lonely experienced a 55% greater symptom severity than those who were not. Additionally, those who reported having many friends had 21% fewer symptoms than those who reported having few or no friends.
“We were shocked,” says Subramanian. “The research paper shows that isolation contributes to stress, deregulates sleep, causes cognitive issues, and leads to a fixation on negative stimuli and rumination over bad thoughts.”
Addressing the challenges of Covid-19
When Covid-19 lockdowns began, people with Parkinson’s had to stop taking part in exercise classes and other group activities in person. Subramanian says: “There was this urgency to get the message out, and to ask, ‘What can we do about this? How can we keep people connecting?’”
This need for ‘social prescribing’ is exacerbated by the possibility that patients might be unlikely to admit being lonely, says Subramanian. “There’s a stigma around being lonely. Some people feel that loneliness means there’s something wrong with them, that they’re not likeable. So we have to think about proactive questioning, and then help people connect with others in the way they need.”
Subramanian saw an immediate need in the Parkinson’s disease community for online support groups – and has since collaborated with the Parkinson and Movement Disorder Alliance to help produce regular virtual support sessions for people in need. The sessions covering topics like physical therapy, mindfulness, yoga, and offering support and social involvement to people with Parkinson’s disease, have attracted hundreds of participants from around the world.
Subramanian has also worked with Parkinson’s disease expert Dr Michael Okun to develop the ‘Parkinson’s Secrets Blog’, publishing regular instalments answering common questions, offering tips and seeking to keep members of the community engaged during Covid-19.
Movement disorder neurologist Dr Indu Subramanian.
Combatting isolation beyond the pandemic
The pandemic is not the only cause of loneliness for people with Parkinson’s disease, says Subramanian. “Non-motor symptoms like depression and anxiety can cause people with Parkinson’s to be anxious about going out in public. Some people get this profound lack of motivation; others start to develop motor symptoms that they find embarrassing, or they feel fatigued or mentally out of it for periods of time.
“There’s a host of things that could prevent patients from happily going out and being part of society. The pandemic has just magnified all those things, because people are stuck in their homes, with connecting made all the more difficult.”
But, she says, connecting virtually with the outside world can help to combat social isolation – whether that means, “joining a support group, putting your name on email lists that can connect you with different activities – anything that resonates with you”.
“Right now, people are hungry for some connection,” Subramanian continues, “so it could also be about getting to know your neighbours, or getting out of your comfort zone to pick up the phone and call someone. There are a lot of barriers in your mind that might stop you from reaching out, but there’s the potential for really great connections to be made.”
Dr Indu Subramanian is a movement disorder neurologist and director of a Veterans Affairs Parkinson’s Disease Research, Education and Clinical Centre in Los Angeles, US. Originally from Canada, Subramanian completed her fellowship training in Movement Disorders at the UCLA School of Medicine, US. She is drawn to integrative treatment for Parkinson’s disease, with a special interest in mind-body approaches and alternative systems of healthcare. Mother to three boys, she enjoys yoga, photography, world travel and jazz.
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.
‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia
Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”